Sai Life Sciences IPO
- IPO Date11 Dec, 2024 to 13 Dec, 2024
- Listing Date18 Dec, 2024
- Face Value₹1 per share
- Issue Price₹522 to ₹549 per share
- Lot Size27 Shares
- Minimum Investment₹14,823
- Listing AtBSE, NSE
- Total Issue Size5,54,21,123 Shares
(aggregating up to ₹3042.62 Cr) - Fresh Issue1,73,04,189 Shares
(aggregating up to ₹950.00 Cr)
- Offer for Sale3,81,16,934 Shares
(aggregating up to ₹2092.62 Cr) - Issue TypeBook Built Issue IPO
- Share holding pre issue19,06,85,340
- Shareholding post issue20,79,89,529
IPO Dates
Closing Date
13 Dec, 2024
Initiation of Refunds
17 Dec, 2024
Listing Date
18 Dec, 2024
11 Dec, 2024
Opening Date
16 Dec, 2024
Basis of Allotment
17 Dec, 2024
Credit of Shares
Sai Life Sciences Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Max) | 1 | - | - |
| S-HNI (Min) | - | - | - |
| S-HNI (Max) | - | - | - |
| Retail (Min) | 1 | - | - |
| B-HNI (Min) | - | - | - |
Sai Life Sciences COMPANY INFORMATION
Sai Life Sciences IPO is a book built issue of Rs 3,042.62 crores. The issue is a combination of fresh issue of 1.73 crore shares aggregating to Rs 950.00 crores and offer for sale of 3.81 crore shares aggregating to Rs 2,092.62 crores. Sai Life Sciences IPO opens for subscription on December 11, 2024 and closes on December 13, 2024. The allotment for the Sai Life Sciences IPO is expected to be finalized on Monday, December 16, 2024. Sai Life Sciences IPO will list on BSE, NSE with tentative listing date fixed as Wednesday, December 18, 2024. Sai Life Sciences IPO price band is set at ₹522 to ₹549 per share. The minimum lot size for an application is 27 Shares. The minimum amount of investment required by retail investors is ₹14,823. The minimum lot size investment for sNII is 14 lots (378 shares), amounting to ₹207,522, and for bNII, it is 68 lots (1,836 shares), amounting to ₹1,007,964. Kotak Mahindra Capital Company Limited, Jefferies India Private Limited, Morgan Stanley India Company Pvt Ltd and Iifl Securities Ltd are the book running lead managers of the Sai Life Sciences IPO, while Kfin Technologies Limited is the registrar for the issue. Refer to Sai Life Sciences IPO RHP for detailed information.
Incorporated in January 1999, Sai Life Sciences Limited researches, develops, and manufactures small-molecule new chemical entities. The company offers tailor-made services to biotech firms and global pharma companies.
In the Financial Year 2024 and for the month ending September 30, 2024, the company provided services to over 280 innovator pharmaceutical companies, including more than 230 in that month alone. Among these clients, the company worked with 18 of the top 25 pharmaceutical companies based on their revenue in the calendar year 2023.The services were offered across countries such as the US, the UK, Europe, and Japan.
The company's business development team consists of 16 experienced and qualified professionals, with six located in the US, nine in the UK and Europe, and one in Japan.
The company has the following service offerings.
- Capabilities in chemistry, manufacturing, and control(“CMC”)/contract development and manufacturing organisations (“CDMO”).
- CRO services include integrated discovery (“Discovery”) capabilities across biology, chemistry, drug metabolism and pharmacokinetics
As of September 30, 2024, the company had 2,353 scientific staff, with the majority of the scientific team holding advanced degrees, including 302 Ph. D.s and 1,475 master’s degrees.
As of September 30, 2024, the company had 3135 employees with capabilities across the CRDMO value chain.
Competitive Strength:
- As an integrated CRDMO, the company provide a complete platform for discovery, development, and manufacturing.
- CRO services include integrated discovery capabilities across biology, chemistry, and drug metabolism and pharmacokinetics.
- CDMO platform with a diverse mix of commercial and under-development molecules
Sai Life Sciences IPO
IPO Overview and Key Highlights
Sai Life Sciences, a leading contract research, development, and manufacturing organization (CRDMO) in the pharmaceutical sector, is launching its Initial Public Offering (IPO). The IPO includes a fresh issue of equity shares aggregating up to ?9,500 million and an Offer for Sale (OFS) of 38,116,934 equity shares. The funds raised will support debt repayment, capacity expansion, and other corporate purposes. Shares will be listed on the NSE and BSE.
Key IPO Details
- Type of Issue: 100% Book Built Issue
- Offer Size: Fresh issue of ?9,500 million and OFS of 38,116,934 equity shares
- Face Value: ?1 per equity share
- Offer Opens: December 11, 2024
- Offer Closes: December 13, 2024
- Listing Exchange: NSE and BSE
Company Overview
Established in 1999 and headquartered in Hyderabad, Sai Life Sciences provides integrated solutions for pharmaceutical companies, spanning from drug discovery to manufacturing. It operates across global markets, serving clients with cutting-edge technology and expertise. Promoters include Kanumuri Ranga Raju, Krishnam Raju Kanumuri, and Sai Quest Syn Private Limited, supported by private equity investors like TPG and HBM.
Financial Overview
Sai Life Sciences has demonstrated strong financial growth, driven by robust global demand for contract research and manufacturing services. IPO proceeds will be utilized to strengthen its balance sheet, enhance operational capacity, and further technological innovations.
Key Strengths of Sai Life Sciences
- Industry Leadership: A key player in the fast-growing global CRDMO market.
- Diverse Offerings: End-to-end pharmaceutical solutions, from research to manufacturing.
- Strategic Market Position: Strong presence in domestic and international pharmaceutical markets.
IPO Pros and Cons
Pros
- Sector Growth: Rising global demand for pharmaceutical research and development services.
- Use of Proceeds: Targeted investments in debt repayment and operational scalability.
- Experienced Management: Promoters and stakeholders bring significant expertise in pharma and investments.
Cons
- Market Sensitivity: Business is highly dependent on global pharmaceutical trends.
- Regulatory Challenges: Compliance with stringent pharma and environmental regulations.
- High Competition: Faces competition from established global players in the CRDMO space.
Risk Factors
Investors should consider the following risks:
- Economic Dependence: Revenue tied to client demand and pharmaceutical sector growth.
- Regulatory Compliance: Adherence to multiple regulatory frameworks across geographies.
- Operational Challenges: Managing expansion without compromising service quality.
Conclusion
The Sai Life Sciences IPO provides an opportunity to invest in a leading player within the global CRDMO market. With its experienced leadership, strong financials, and diverse service offerings, the company is positioned for sustainable growth. However, investors must assess risks such as regulatory dependencies and competition before investing.
FAQs About Sai Life Sciences Ipo
Sai Life Sciences IPO will open on 11 Dec, 2024 and close on 13 Dec, 2024. Investors must apply within this period to participate.
The Sai Life Sciences IPO price band is set between ₹522.00 and ₹549.00 per share. The minimum lot size is 27, requiring an investment of at least ₹14823.00.
The Sai Life Sciences IPO shares are expected to be listed on 18 Dec, 2024, subject to regulatory approvals and final allotment.
You can track your Sai Life Sciences IPO application status on the registrar’s website: Link Intime or KFintech using your PAN, application number, or DP ID
The Sai Life Sciences IPO will be listed on major stock exchanges such as NSE and BSE, where you can trade shares once they are listed.